Nicolucci A, Kovacs Burns K, Holt RI, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. Diabet Med. 2013;30:767-777. Abstract
Kovacs Burns K, Nicolucci A, Holt RI, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2): cross-national benchmarking indicators for family members living with people with diabetes. Diabet Med. 2013;30:778-788. Abstract
Holt RI, Nicolucci A, Kovacs Burns K, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2): cross-national comparisons on barriers and resources for optimal care – healthcare professional perspective. Diabet Med. 2013;30:789-798. Abstract
Willaing I, Peyrot M. Active involvement of people with diabetes and support for self-management. Oral presentation at: The World Diabetes Congress; December 5, 2013; Melbourne, Australia.
Parchman ML, Zeber JE, Palmer RF. Participatory Decision Making, Patient Activation, Medication Adherence, and Intermediate Clinical Outcomes in Type 2 Diabetes: A STARNet Study. Ann Fam Med. 2010;8:410-417. Abstract
Brunton S, Gough S, Hicks D, et al. A look into the future: improving diabetes care by 2015. Curr Med Res. 2011;27:65-72. Abstract
Ali MK, McKeever Bullard K, Saaddine JB, et al. Achievement of goals in US diabetes care, 1999-2010. N Engl J Med. 2013;368:1613-1624. Abstract
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520. Abstract
Aronson R. The role of comfort and discomfort in insulin therapy. Diabetes Technol Ther. 2012;14:741-747. Abstract
Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Diabetes Care. 2005;28:2673-2679. Abstract
Perfetti R. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technol Ther. 2010;12 Suppl 1:S79-S85. Abstract
Karter AJ, Subramanian U, Saha C, et al. Barriers to Insulin Initiation. Diabetes Care. 2010;33:733-735. Abstract
Burke SD, Sherr D, Lipman RD. Partnering with diabetes educators to improve patient outcomes. Diabetes Metab Syndr Obes. 2014;7:45-53. Abstract
Bodenheimer T, Handley MA. Goal-setting for behavior change in primary care: an exploration and status report. Patient Educ Couns. 2009;76:174-180. Abstract
Russell-Minda E, Jutai J, Speechley M, et al. Health technologies for monitoring and managing diabetes: a systematic review. J Diabetes Sci Technol. 2009;3:1460-1471. Abstract
Pastors JG, Warshaw H, Daly A, et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care. 2002;25:608-613. Abstract
WebMD Survey. Non-insulin injectable adherence among diabetes patients. October 1, 2012. Accessed March 4, 2014.
Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379. Abstract
Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs – insights from the rosiglitazone experience. N Engl J Med. 2013;369:1285-1287. Abstract
Farxiga® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2014.
Invokana® [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2013.
Scheen AJ. Pharmacokinetic and pharmacodynamics profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53:213-225. Abstract
Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycemia with insulin aspart: a double-blind, randomized, crossover trial in subjects with type 1 diabetes. Diabet Med. 2004;21:769-775. Abstract
Tentolouris N, Kyriazopoulou V, Makrigiannis D, et al. Intensification of insulin therapy in patients with type 2 diabetes: a retrospective, non-interventional cohort study of patients treated with insulin glargine or biphasic human insulin in daily clinical practice. Diabetol Metab Syndr. 2013;5:43.
Nauck MA. A critical analysis of the clinical use of incretin-based therapies. Diabetes Care. 2013;36:2126-2132. Abstract
Singh S, Chang HY, Richards TM, et al. Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus. JAMA Intern Med. 2013;173:534-539. Abstract
Yang L, He Z, Tang X, et al. Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25:225-231. Abstract
Drucker DJ, Sherman SI, Bergenstal RM, et al. The safety of incretin-based therapies – review of the scientific evidence. J Clin Endocrinol Metab. 2011;96:2027-2031. Abstract
Bydureon® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2013.
Byetta® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2013.
Victoza® [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2013.
Del Canale S, Louis DZ, Maio V, et al. The relationship between physician empathy and disease complications: an empirical study of primary care physicians and their diabetic patients in Parma, Italy. Acad Med. 2012;87:1243-1249. Abstract
Hojat M, Louis DZ, Markham FW, et al. Physicians’ empathy and clinical outcomes for diabetic patients. Acad Med. 2011;86:359-364. Abstract

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author(s)

Luigi F. Meneghini, MD, MBA

Professor of Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, Texas

Disclosures

Disclosure: Luigi F. Meneghini, MD, MBA, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Halozyme Therapeutics; Novo Nordisk; Sanofi;
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; MannKind Corporation; Pfizer Inc; Sanofi

Dr Meneghini does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Meneghini does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

John E. Anderson, MD

President, The Frist Clinic, Nashville, Tennessee

Disclosures

Disclosure: John E. Anderson, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Janssen Pharmaceutical Products, L.P.; Lilly; Sanofi;
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Janssen Pharmaceutical Products, L.P.;

Dr Anderson does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Anderson does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

Anne G. Le, PharmD, RPh

Lead Scientific Director, Medscape, LLC

Disclosures

Disclosure: Anne G. Le, PharmD, RPh, has disclosed no relevant financial relationships.

Karen Badal, MD, MPH

Associate Scientific Director, Medscape, LLC

Disclosures

Disclosure: Karen Badal, MD, MPH, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

CME/CE

Adherence to Type 2 Diabetes Management Plans: Developing Successful Patient Interactions

Authors: Luigi F. Meneghini, MD, MBA; John E. Anderson, MD
CME/CE Released: 4/14/2014
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 4/14/2015

Start Activity

Target Audience and Goal Statement

This activity is intended for family and internal medicine physicians, endocrinologists, diabetologists, nurse practitioners, physician assistants, and nurses.

The goal of this activity is to recognize the importance of empathy in fostering physician-patient partnerships, improving patient adherence to therapies for type 2 diabetes (T2D), as well as improving awareness of solutions for overcoming barriers to patient adherence to therapies for T2D.

Upon completion of this activity, participants will be able to:

Propose strategies to build effective clinician-patient partnerships to overcome barriers to treatment adherence in patients with T2D
Identify the importance of empathy in addressing patient concerns that can lead to nonadherence to treatment plans for T2D

Disclosures

Author(s)

Luigi F. Meneghini, MD, MBA

Professor of Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, Texas

Disclosures

Disclosure: Luigi F. Meneghini, MD, MBA, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Halozyme Therapeutics; Novo Nordisk; Sanofi;
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; MannKind Corporation; Pfizer Inc; Sanofi

Dr Meneghini does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Meneghini does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

John E. Anderson, MD

President, The Frist Clinic, Nashville, Tennessee

Disclosures

Disclosure: John E. Anderson, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Janssen Pharmaceutical Products, L.P.; Lilly; Sanofi;
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Janssen Pharmaceutical Products, L.P.;

Dr Anderson does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Anderson does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

Anne G. Le, PharmD, RPh

Lead Scientific Director, Medscape, LLC

Disclosures

Disclosure: Anne G. Le, PharmD, RPh, has disclosed no relevant financial relationships.

Karen Badal, MD, MPH

Associate Scientific Director, Medscape, LLC

Disclosures

Disclosure: Karen Badal, MD, MPH, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For Nurses

Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 0.75 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Diabetes & Endocrinology

CME/CE

Adherence to Type 2 Diabetes Management Plans: Developing Successful Patient Interactions

Authors: Luigi F. Meneghini, MD, MBA; John E. Anderson, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME/CE Released: 4/14/2014

Valid for credit through: 4/14/2015

processing....

This feature requires the newest version of Flash. You can download it here.

CME/CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Author(s)

Luigi F. Meneghini, MD, MBA

John E. Anderson, MD

Editors

Anne G. Le, PharmD, RPh

Karen Badal, MD, MPH

CME Reviewer(s)

Nafeez Zawahir, MD

Nurse Planner

Amy Bernard, MS, BSN, RN-BC

CME/CE

Adherence to Type 2 Diabetes Management Plans: Developing Successful Patient Interactions

Target Audience and Goal Statement

Disclosures

Author(s)

Luigi F. Meneghini, MD, MBA

John E. Anderson, MD

Editors

Anne G. Le, PharmD, RPh

Karen Badal, MD, MPH

CME Reviewer(s)

Nafeez Zawahir, MD

Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Adherence to Type 2 Diabetes Management Plans: Developing Successful Patient Interactions